GEN Exclusives

More »

GEN News Highlights

More »
Mar 3, 2009

Sigma-Aldrich Purchases NextGen’s Electrophoresis Franchise

  • NextGen Sciences divested its electrophoresis business to Sigma-Aldrich for an up-front fee and royalties for three years. This completes NextGen’s realignment to a biomarker services business.

    Under the deal with Sigma-Aldrich, NextGen has sold its automated gel casting unit called a2DEoptimizer™ and the range of large format precast gels known as optigels™. Sigma-Aldrich will focus primarily on the supply of optigels, initially to the North American and European markets.

    In December 2008, NextGen sold its gene-to-protein automation and software business to eXeTek, a spinout led by two former NextGen employees. NextGen also acquired a 24% stake in eXeTek at the time and will receive 5% royalties for three years.

    Launched in November 2007, NextGen Sciences’ service portfolio called biomarkerexpress™ includes biomarker discovery, assay development, and testing.



Related content

Jobs

GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
 Searching...
More »

GEN Poll

More » Poll Results »

Alzheimer's Therapies

Do you think an effective treatment for Alzheimer’s will be found within the next 10–15 years?